GlassScriptPhysician profile
Rusdeep Mundae
NPI 1811488687
$5,849.21
in general payments reported to CMS, 2019-2025
23 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $423 · 2023: $1,323 · 2024: $1,671 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,966 · Honoraria: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,966.00 |
| Honoraria | $460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,068.26 | 2022-2025 | Ngenuity, Constellation, Argos |
| Biotissue Holdings INC. | $916.84 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $571.03 | 2023-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $460.00 | 2024 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $343.95 | 2024-2025 | Acthar |
| Genentech USA, INC. | $320.06 | 2023-2025 | Vabysmo |
| Abbvie INC. | $303.60 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $240.98 | 2022-2025 | Syfovre |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $220.41 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $212.90 | 2025 | Xdemvy |
| Genentech, INC. | $182.86 | 2023-2025 | Susvimo, Vabysmo |
| Dutch Ophthalmic, USA | $171.51 | 2023 | Eva, Combined Machine, Tissueblue |
| Astellas Pharma US INC | $153.97 | 2023-2024 | Izervay |
| Eyepoint US, INC. | $146.80 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $136.95 | 2025 | Tecnis Simplicity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $124.58 | 2024 | Eylea Hd, Eylea |
| Ani Pharmaceuticals, INC. | $57.74 | 2024-2025 | Iluvien, Purified Cortrophin Gel |
| Dompe US, INC. | $52.89 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $48.25 | 2025 | Xipere, Xiidra, Miebo |
| Thea Pharma INC. | $43.88 | 2024-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $33.33 | 2024 | |
| Oyster Point Pharma, INC. | $20.77 | 2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $17.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rusdeep Mundae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.